drugset / Trial / NCT00077675
Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
RandomizedParallel-groupTriple-blindTreatment
Summary
Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 (Telavancin) can control infections and whether the drug is safe to give to patients.
Timeline
- Start
- 2004-02
- Primary completion
- 2004-09
- Completion
- 2004-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telavancin | Other / unclassified | 7.5 mg/kg | Intravenous |
| Subject | Telavancin | Other / unclassified | 10 mg/kg | Intravenous |
| Comparator | Vancomycin | Other / unclassified | 1 g | Intravenous |
| Comparator | cloxacillin | Other / unclassified | 0.5 g | Intravenous |
| Comparator | cloxacillin | Other / unclassified | 1 g | Intravenous |
| Comparator | nafcillin | Small molecule | 2 g | Intravenous |
| Comparator | oxacillin | Small molecule | 2 g | Intravenous |